SCHEMBL8908785

SCHEMBL8908785

CCCCCCCCCCCCCCCCCC(=O)OCC(COC(=O)CCCCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 1.00
LMNA P02545 1/20 1.00
PRKCA P17252 4/20 0.84
PRKCE Q02156 2/20 0.84
PRKCQ Q04759 2/20 0.84
PRKCD Q05655 2/20 0.84
LPAR3 Q9UBY5 7/20 0.77
LPAR1 Q92633 4/20 0.77
ENPP2 Q13822 3/20 0.77
SMN1; SMN2 Q16637 1/20 0.77
LPAR2 Q9HBW0 2/20 0.75
MAPT P10636 1/20 0.68
MAPK1 P28482 1/20 0.68

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Tripalmitin SCHEMBL3239772 1.00 ALDH1A1 (1.00) ALDH1A1LMNAPRKCAPRKCEPRKCQ
Tripalmitin SCHEMBL2017107 1.00 ALDH1A1 (1.00) ALDH1A1LMNAPRKCAPRKCEPRKCQ
SCHEMBL896399 1.00 ALDH1A1 (1.00) ALDH1A1LMNAPRKCAPRKCEPRKCQ
SCHEMBL24334742 1.00 ALDH1A1 (1.00) ALDH1A1LMNAPRKCAPRKCEPRKCQ
SCHEMBL24333834 1.00 ALDH1A1 (1.00) ALDH1A1LMNAPRKCAPRKCEPRKCQ
SCHEMBL24333843 1.00 ALDH1A1 (1.00) ALDH1A1LMNAPRKCAPRKCEPRKCQ
SCHEMBL23612380 1.00 ALDH1A1 (1.00) ALDH1A1LMNAPRKCAPRKCEPRKCQ
SCHEMBL24334040 1.00 ALDH1A1 (1.00) ALDH1A1LMNAPRKCAPRKCEPRKCQ
SCHEMBL22973398 1.00 ALDH1A1 (1.00) ALDH1A1LMNAPRKCAPRKCEPRKCQ
SCHEMBL9717938 1.00 ALDH1A1 (1.00) ALDH1A1LMNAPRKCAPRKCEPRKCQ

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11899027-B2 Diagnostic methods based on lipid profiles RUBIO METABOLOMICS, S.L.U. (ES) 2024-02-13 US claimed
US-20220308075-A1 LIPID PROFILING METHODS FOR PREDICTING POSITIVE PREGNANCY OUTCOME HADASIT MEDICAL RESEARCH SERVICES & DEVELOPMENT LTD. (IL) 2022-09-29 US claimed
CN-114544924-A Application of glyceride in disease prediction 中国科学院上海营养与健康研究所 2022-05-27 CN claimed
US-20200155575-A1 PHARMACEUTICAL COMPOSITION AND METHODS LIPOCINE INC. (US) 2020-05-21 US claimed
US-20190269700-A1 PHARMACEUTICAL COMPOSITION AND METHODS LIPOCINE INC. (US) 2019-09-05 US claimed
US-20180078568-A1 PHARMACEUTICAL COMPOSITION AND METHODS LIPOCINE INC. (US) 2018-03-22 US claimed
US-20160184324-A1 PHARMACEUTICAL COMPOSITION AND METHODS LIPOCINE INC. (US) 2016-06-30 US claimed
US-20260000768-A1 APPLICATION OF COMPOUND OR TRADITIONAL CHINESE MEDICINE EXTRACT IN PREPARATION OF NUCLEIC ACID DELIVERY AGENT, AND RELATED PRODUCTS BEIJING BAISHIHEKANG PHARMACEUTICAL TECH BSJPHARMA CO LTD (CN) 2026-01-01 US disclosed
US-20250345290-A1 APPLICATION OF COMPOUND OR TRADITIONAL CHINESE MEDICINE EXTRACT IN PREPARATION OF NUCLEIC ACID DELIVERY AGENT AND RELATED PRODUCTS THEREOF BEIJING BAISHIHEKANG PHARMACEUTICAL TECH BSJPHARMA CO LTD (CN) 2025-11-13 US disclosed
US-20250264481-A1 METHODS FOR PREDICTION AND EARLY DETECTION OF DIABETES Baker Heart and Diabetes Institute (AU) 2025-08-21 US disclosed
US-12313634-B2 Methods for prediction and early detection of diabetes ZORA BIOSCIENCES OY (FI) 2025-05-27 US disclosed
US-20250166821-A1 METHODS FOR PREDICTION OF TREATMENT RESPONSE IN NON-ALCOHOLIC FATTY LIVER DISEASE SAGIMET BIOSCIENCES INC. 2025-05-22 US disclosed
US-12280114-B2 Extraction of plant source “medicinal soup” and manual preparation of “herbal medicine” and related products INSTITUTE OF BASIC MEDICAL SCIENCES (CN) 2025-04-22 US disclosed
US-20160193225-A1 (17-ß)-3-OXOANDROST-4-EN-17-YL UNDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE LIPOCINE INC. (US) 2016-07-07 US disclosed
US-20160184324-A1 PHARMACEUTICAL COMPOSITION AND METHODS LIPOCINE INC. (US) 2016-06-30 US disclosed
WO-2016033611-A1 (17-β)-3-OXOANDROST-4-EN-17-YL UNDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE LIPOCINE INC. (US) 2016-03-03 WO disclosed
WO-2016033536-A1 PHARMACEUTICAL COMPOSITION AND METHODS LIPOCINE INC. (US) 2016-03-03 WO disclosed
US-5690985-A SELECTING A BLEND OF SPREAD FATS, ADDING A 2-ELAIDOYLTRIACYLGLYCEROL AND FORMING AN EDIBLE EMULSION VAN DEN BERGH FOODS CO., DIVISION OF CONOPCO, INC. (US) 1997-11-25 US disclosed
EP-0498487-B1 Improvements in edible fats UNILEVER NV (NL) 1995-04-26 EP disclosed
EP-0498487-A1 Improvements in edible fats UNILEVER N.V. (NL) 1992-08-12 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260000768-A1 APPLICATION OF COMPOUND OR TRADITIONAL CHINESE MEDICINE EXTRACT IN PREPARATION OF NUCLEIC ACID DELIVERY AGENT, AND RELATED PRODUCTS FABP2, NSUN2, TRDMT1 ALDH1A1 3856/4885LMNA 118/4885PRKCA 1593/4885
US-20250345290-A1 APPLICATION OF COMPOUND OR TRADITIONAL CHINESE MEDICINE EXTRACT IN PREPARATION OF NUCLEIC ACID DELIVERY AGENT AND RELATED PRODUCTS THEREOF TRDMT1, HNRNPAB, HNRNPA1 ALDH1A1 4559/4885LMNA 309/4885PRKCA 2378/4885
US-12280114-B2 Extraction of plant source “medicinal soup” and manual preparation of “herbal medicine” and related products CHMP4B, FIP1L1, LIPC ALDH1A1 3396/4885LMNA 315/4885PRKCA 55/4885
US-20250166821-A1 METHODS FOR PREDICTION OF TREATMENT RESPONSE IN NON-ALCOHOLIC FATTY LIVER DISEASE ACACB, ACACA, ACLY ALDH1A1 554/4885LMNA 3283/4885PRKCA 1036/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.